CVTX starts Ranexa Phase III

CV Therapeutics (CVTX) began an international Phase III trial of Ranexa ranolazine in about 500 patients with chronic angina who remain symptomatic despite daily treatment with amlodipine. The primary endpoint of the double-blind, placebo-controlled study is angina frequency. Patients will remain on amlodipine and be randomized to receive 1,000 mg of Ranexa or placebo twice daily for six weeks. CVTX said the trial, for which it has an SPA, is 95% powered to detect a statistically significant reduction in angina frequency due to Ranexa. ...